The estimated Net Worth of Ronen Tchelet is at least $315 Tisíc dollars as of 7 July 2022. Ronen Tchelet owns over 8,943 units of Dyadic International stock worth over $1,361 and over the last 5 years he sold DYAI stock worth over $0. In addition, he makes $313,836 as Vice President of Research and Business Development at Dyadic International.
Sign up
Ronen Tchelet DYAI stock SEC Form 4 insiders trading
Ronen has made over 9 trades of the Dyadic International stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 8,943 units of DYAI stock worth $14,041 on 7 July 2022.
The largest trade he's ever made was exercising 20,000 units of Dyadic International stock on 18 June 2019 worth over $28,200. On average, Ronen trades about 7,263 units every 74 days since 2019. As of 7 July 2022 he still owns at least 1,089 units of Dyadic International stock.
You can see the complete history of Ronen Tchelet stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ronen Tchelet biography
Dr. Ronen Tchelet Ph.D. serves as Vice President of Research and Business Development of the Company. Since joining Dyadic, Dr. Tchelet has been a key contributor to Dyadic’s transformation into a pharmaceutical biotech company. Prior to joining Dyadic, Dr. Tchelet was the founder and Managing Director of Codexis Laboratories Hungary kft. (“CLH”) and a Vice President of Codexis Inc. from 2007 through 2014. While at CLH, Dr. Tchelet established a state-of-the-art laboratory for strain engineering and all aspects of fermentation including process optimization and scale up. During this time period, Dr. Tchelet also led a collaboration that successfully developed C1 technology for the Biofuel and the Bio-Industrial enzymes applications. Dr. Tchelet’s experience in the pharmaceutical industry includes prior employment at TEVA Pharmaceutical Industries LTD (“TEVA”), API Division during the late 2000’s to 2006. While at TEVA, he served as a Chief Technology Officer of Biotechnology and led TEVA’s Biotechnology Research and Development fermentation plant in Hungary. Also, during the period of 2000 through 2005, Dr. Tchelet was the Manager of Quality Assurance for TEVA’s flag ship innovative drug, COPAXONE®. Throughout his career, Dr. Tchelet has led several Biotechnology projects that have encompassed all aspects of research and development, operations management, and manufacturing of API’s and biologics. Dr. Tchelet received his Ph.D. in Molecular Microbiology and Biotechnology from Tel Aviv University in 1993 and did his postdoctoral work as an EERO fellow at the Institute of Environmental Science and Technology (EAWAG) in Switzerland.
What is the salary of Ronen Tchelet?
As the Vice President of Research and Business Development of Dyadic International, the total compensation of Ronen Tchelet at Dyadic International is $313,836. There are 5 executives at Dyadic International getting paid more, with Mark Emalfarb having the highest compensation of $1,074,050.
How old is Ronen Tchelet?
Ronen Tchelet is 62, he's been the Vice President of Research and Business Development of Dyadic International since 2016. There are 7 older and 3 younger executives at Dyadic International. The oldest executive at Dyadic International, Inc. is Jack Kaye, 76, who is the Independent Director.
What's Ronen Tchelet's mailing address?
Ronen's mailing address filed with the SEC is C/O DYADIC INTERNATIONAL, INC., 1044 NORTH U.S. HIGHWAY ONE, SUITE 201, JUPITER, FL, 33477-5094.
Insiders trading at Dyadic International
Over the last 6 years, insiders at Dyadic International have traded over $118,246,658,250 worth of Dyadic International stock and bought 27,000 units worth $100,230 . The most active insiders traders include Mark A Emalfarb, Ronen Tchelet a Seth Herbst. On average, Dyadic International executives and independent directors trade stock every 73 days with the average trade being worth of $54,365. The most recent stock trade was executed by Barry Buckland on 11 June 2024, trading 11,793 units of DYAI stock currently worth $18,751.
What does Dyadic International do?
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-S-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and research collaborations with Jiangsu Hengrui Medicine, Serum Institute of India Pvt., Ltd., and WuXi Biologics. It also has a collaboration with TurtleTree Scientific Pte. Ltd. to develop various recombinant protein growth factors; and a partnership agreement with Medytox, Inc. and Syngene International Limited to develop COVID-19 vaccines and/or boosters. The company was founded in 1979 and is headquartered in Jupiter, Florida.
What does Dyadic International's logo look like?
Complete history of Ronen Tchelet stock trades at Dyadic International
Dyadic International executives and stock owners
Dyadic International executives and other stock owners filed with the SEC include:
-
Mark Emalfarb,
President, Chief Executive Officer, Director -
Mark A. Emalfarb,
Founder, CEO, Pres & Director -
Matthew Jones,
Managing Director - Business Development and Licensing -
Ping Rawson,
Chief Financial Officer, Chief Accounting Officer -
Matthew S. Jones,
Managing Director of Bus. Devel. & Licensing -
Ronen Tchelet,
Vice President of Research and Business Development -
Dr. Ronen Tchelet Ph.D.,
VP of Research & Bus. Devel. -
Jack Kaye,
Independent Director -
Arindam Bose,
Independent Director -
Michael Tarnok,
Independent Chairman of the Board -
Seth Herbst,
Independent Director -
Barry Buckland,
Independent Director -
Ana Gómez Rodriguez,
Sec. of the Board -
Joseph P. Hazelton,
Chief Bus. Officer -
Patrick K. Lucy,
Director -
Trust Under Agreement Dated...,
10% owner -
Joseph P Hazelton,
Chief Business Officer